Literature DB >> 13763191

Demonstration of the sequential development of vaccinial antigens and virus in infected cells: observations with cytochemical and differential fluorescent procedures.

P C LOH, J L RIGGS.   

Abstract

Virus-induced alterations in vaccinia virus-infected HeLa cells have been followed by immunofluorescent and cytochemical techniques. In a time sequence study, infected cells show an early increase in cytoplasmic RNA content, followed by appearance of centers of viral DNA synthesis in the cytoplasm. The centers of synthesis were detected at 4 hours post infection, with the acridine orange fluorochrome stain as compared to 6 hours with Feulgen and methyl green-pyronin stains. Marginal fragmentation of the inclusion bodies was seen at 8 to 10 hours post infection, and appears to coincide with the first increase in cell-associated virus. With the immunofluorescent technique, it was found that the LS antigen of the virus can be detected at about 4 hours post infection. This is followed at 5 to 6 hours post infection by the appearance of the NP antigen. Both antigens are found only in the cytoplasm, and precede the appearance of the infective particle. The HA antigen, a by-product of virus-cell interaction, is not seen until about 10 hours post infection; that is, several hours after the appearance of both the LS and NP antigens, and only after the appearance of mature virus. The successful application of the use of two immune sera, each labeled with a different fluorescent dye for the simultaneous visualization of two antigens within a cell, is reported. Using this technique, the sites of LS and NP antigen synthesis, were easily differentiated. The intimate mixing of the two antigens at a later stage appears to coincide with the fragmentation of the inclusion body and the first detectable increase in cell-associated virus. The evidence obtained strongly suggests that the typical inclusion body observed in vaccinia-infected cells is composed mainly of the NP antigen.

Entities:  

Keywords:  ANTIGENS; VACCINIA/virology; VIRUSES/culture

Mesh:

Substances:

Year:  1961        PMID: 13763191      PMCID: PMC2137444          DOI: 10.1084/jem.114.1.149

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  A simple fractionation method for preparation of fluorescein-labeled gamma globulin.

Authors:  J L RIGGS; P C LOH; W C EVELAND
Journal:  Proc Soc Exp Biol Med       Date:  1960-12

2.  Isothiocyanate compounds as fluorescent labeling agents for immune serum.

Authors:  J L RIGGS; R J SEIWALD; J H BURCKHALTER; C M DOWNS; T G METCALF
Journal:  Am J Pathol       Date:  1958 Nov-Dec       Impact factor: 4.307

3.  Biochemical studies on vaccinia virus in cultured cells. I. Incorporation of adenine-8-C14 into normal and infected cells.

Authors:  W K JOKLIK; J M RODRICK
Journal:  Virology       Date:  1959-11       Impact factor: 3.616

4.  Fluorescence microscopy in the study of nucleic acids; histochemical observations on cellular and virus nucleic acids.

Authors:  J A ARMSTRONG; J S NIVEN
Journal:  Nature       Date:  1957-12-14       Impact factor: 49.962

5.  ELEMENTARY BODIES OF VACCINIA.

Authors:  J E Smadel; C L Hoagland
Journal:  Bacteriol Rev       Date:  1942-06

6.  STUDIES ON THE SOLUBLE PRECIPITABLE SUBSTANCES OF VACCINIA : II. THE SOLUBLE PRECIPITABLE SUBSTANCES OF DERMAL VACCINE.

Authors:  J Craigie; F O Wishart
Journal:  J Exp Med       Date:  1936-10-31       Impact factor: 14.307

7.  Intracellular forms of pox viruses as shown by the electron microscope (Vaccinia, Ectromelia, Molluscum Contagiosum).

Authors:  W H GAYLORD; J L MELNICK
Journal:  J Exp Med       Date:  1953-08       Impact factor: 14.307

8.  The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture.

Authors:  H EAGLE
Journal:  J Exp Med       Date:  1955-07-01       Impact factor: 14.307

9.  Localization of antigen in tissue cells; improvements in a method for the detection of antigen by means of fluorescent antibody.

Authors:  A H COONS; M H KAPLAN
Journal:  J Exp Med       Date:  1950-01-01       Impact factor: 14.307

10.  On the role of ribonucleic acid in animal virus synthesis. II. Studies with ribonuclease.

Authors:  I TAMM; R BABLANIAN
Journal:  J Exp Med       Date:  1960-03-01       Impact factor: 14.307

View more
  19 in total

1.  MESSENGER RNA IN CELLS INFECTED WITH VACCINIA VIRUS.

Authors:  Y BECKER; W K JOKLIK
Journal:  Proc Natl Acad Sci U S A       Date:  1964-04       Impact factor: 11.205

2.  THE USE OF IMMUNOFLUORESCENCE IN THE RAPID PRESUMPTIVE DIAGNOSIS OF VARIOLA.

Authors:  D KIRSH; R KISSLING
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

3.  [FREE HEMAGGLUTININ AS A CRITERION FOR THE PROPAGATION OF VACCINIA VIRUS IN CHICK EMBRYO CELL CULTURES].

Authors:  E MANNWELLER
Journal:  Arch Gesamte Virusforsch       Date:  1964

4.  Modification of fluorescent-antibody procedures employing crystalline tetramethylrhodamine isothiocyanate.

Authors:  M L SMITH; T R CARSKI; C W GRIFFIN
Journal:  J Bacteriol       Date:  1962-06       Impact factor: 3.490

Review 5.  Monkeypox virus.

Authors:  C T Cho; H A Wenner
Journal:  Bacteriol Rev       Date:  1973-03

6.  Sequential protein synthesis following vaccinia virus infection.

Authors:  B Moss; N P Salzman
Journal:  J Virol       Date:  1968-10       Impact factor: 5.103

7.  Yaba tumor poxvirus synthesis in vitro. 3. Growth kinetics.

Authors:  D S Yohn; V A Haendiges; E De Harven
Journal:  J Bacteriol       Date:  1966-05       Impact factor: 3.490

8.  Assay of variola virus by the fluorescent cell-counting technique.

Authors:  N Hahon
Journal:  Appl Microbiol       Date:  1965-11

9.  Cytopathologic changes in fowlpox (turkey origin) inclusion body formation.

Authors:  N F Cheville
Journal:  Am J Pathol       Date:  1966-10       Impact factor: 4.307

10.  Vaccinia virus infection of synchronized pig kidney cells.

Authors:  R M Groyon; A J Kniazeff
Journal:  J Virol       Date:  1967-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.